Medimmune Ventures, Inc. Sells 133,906 Shares of G1 THERAPEUTICS (GTHX) Stock
G1 THERAPEUTICS (NASDAQ:GTHX) major shareholder Medimmune Ventures, Inc. sold 133,906 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $19.75, for a total value of $2,644,643.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Medimmune Ventures, Inc. also recently made the following trade(s):
- On Monday, November 20th, Medimmune Ventures, Inc. sold 200,000 shares of G1 THERAPEUTICS stock. The stock was sold at an average price of $20.01, for a total value of $4,002,000.00.
G1 THERAPEUTICS (NASDAQ GTHX) traded down $0.62 on Tuesday, reaching $19.01. The company had a trading volume of 111,800 shares, compared to its average volume of 99,484. G1 THERAPEUTICS has a 1-year low of $12.04 and a 1-year high of $28.67.
Several large investors have recently made changes to their positions in GTHX. California State Teachers Retirement System bought a new stake in shares of G1 THERAPEUTICS in the third quarter worth about $319,000. Schwab Charles Investment Management Inc. purchased a new position in shares of G1 THERAPEUTICS during the third quarter valued at approximately $364,000. American International Group Inc. purchased a new position in shares of G1 THERAPEUTICS during the third quarter valued at approximately $130,000. Chartwell Investment Partners LLC increased its position in shares of G1 THERAPEUTICS by 5.0% during the third quarter. Chartwell Investment Partners LLC now owns 92,558 shares of the company’s stock valued at $2,303,000 after acquiring an additional 4,388 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of G1 THERAPEUTICS during the third quarter valued at approximately $568,000. 43.25% of the stock is currently owned by hedge funds and other institutional investors.
G1 THERAPEUTICS Company Profile
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with MarketBeat.com's FREE daily email newsletter.